The pivotal IMpower133 trial revealed that incorporating the anti-PD-L1 monoclonal antibody atezolizumab into standard chemotherapy (carboplatin + etoposide) notably extended overall survival from a median of 10.3 months to 12.3 months, thereby setting immune combination chemotherapy as the new first-line standard for ES-SCLC (7). The gene discussed is CD274; the disease is small cell lung carcinoma.